VolitionRx’s (VNRX) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of VolitionRx (NYSE:VNRX) in a research report released on Tuesday morning,Benzinga reports. They currently have a $5.00 target price on the stock.

Several other research analysts also recently commented on the company. Benchmark reiterated a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. StockNews.com began coverage on VolitionRx in a report on Tuesday. They issued a “sell” rating on the stock.

VolitionRx Trading Up 5.1 %

VNRX opened at $0.61 on Tuesday. The company has a market cap of $56.60 million, a P/E ratio of -1.70 and a beta of 1.09. The business’s 50-day moving average price is $0.61 and its 200-day moving average price is $0.65. VolitionRx has a 12 month low of $0.43 and a 12 month high of $1.10.

Insider Activity at VolitionRx

In other VolitionRx news, Director Guy Archibald Innes purchased 174,764 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The shares were bought at an average price of $0.57 per share, for a total transaction of $99,615.48. Following the acquisition, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Cameron John Reynolds purchased 139,811 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now owns 2,117,404 shares in the company, valued at $1,206,920.28. This trade represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 358,266 shares of company stock worth $204,212 in the last 90 days. Company insiders own 12.80% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Two Sigma Securities LLC purchased a new position in shares of VolitionRx during the 4th quarter worth approximately $29,000. Millennium Management LLC purchased a new position in shares of VolitionRx during the 4th quarter worth approximately $36,000. Northern Trust Corp grew its holdings in shares of VolitionRx by 32.0% during the 4th quarter. Northern Trust Corp now owns 117,875 shares of the company’s stock worth $71,000 after acquiring an additional 28,579 shares during the period. Geode Capital Management LLC grew its holdings in shares of VolitionRx by 15.1% during the 3rd quarter. Geode Capital Management LLC now owns 730,448 shares of the company’s stock worth $439,000 after acquiring an additional 95,900 shares during the period. Finally, Lagoda Investment Management L.P. grew its holdings in shares of VolitionRx by 24.3% during the 4th quarter. Lagoda Investment Management L.P. now owns 7,576,000 shares of the company’s stock worth $4,546,000 after acquiring an additional 1,481,000 shares during the period. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.